Cellevate Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
23
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$2.29M
- Investors
-
7
Cellevate General Information
Description
Developer of cell culture technology intended to create nanofiber-based systems for biomanufacturing processes. The company offers nanofiber microcarriers, cell culture systems, 3D cell culture platforms, and bioprocessing materials, enabling biopharmaceutical companies and researchers access to tools for cell and gene therapy production and vaccine manufacturing.
Contact Information
Website
www.cellevate.comCorporate Office
- Medicon Village
- Scheelevägen 8
- 223 63 Lund
- Sweden
Corporate Office
- Medicon Village
- Scheelevägen 8
- 223 63 Lund
- Sweden
Cellevate Timeline
Cellevate Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Later Stage VC | 30-Mar-2026 | $2.29M | Completed | Generating Revenue | ||
| 7. Later Stage VC | 16-Sep-2024 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 29-Jun-2023 | Completed | Generating Revenue | |||
| 5. Grant | 23-Mar-2022 | Completed | Generating Revenue | |||
| 4. Seed Round | 04-Dec-2018 | Completed | Generating Revenue | |||
| 3. Angel (individual) | 01-Jan-2017 | Completed | Startup | |||
| 2. Accelerator/Incubator | 01-Jan-2017 | Completed | Startup | |||
| 1. Accelerator/Incubator | 01-Jan-2016 | Completed | Startup |
Cellevate Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 6,816 | $68.01 | $68.01 | 1x | $68.01 | 5.15% | ||
| Ordinary | 8,550 | $23.86 | $23.86 | 1x | $23.86 | 6.46% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Cellevate Patents
Cellevate Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026132129-A1 | Passaging of cells | Pending | 20-Dec-2024 | ||
| WO-2025252819-A1 | Process for culturing stem cells | Pending | 04-Jun-2024 | ||
| WO-2025163164-A1 | Production of adeno-associated viruses | Pending | 31-Jan-2024 | ||
| WO-2024227924-A1 | Method for obtaining a cytokine response | Inactive | 03-May-2023 | ||
| JP-2026501008-A | Nanofiber scaffolds for cell culture | Pending | 21-Dec-2022 | C12M25/14 |
Cellevate Signals
Cellevate Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Almi Invest | Venture Capital | Minority | ||
| Industrifonden | Venture Capital | Minority | ||
| Onsight Ventures | Venture Capital | Minority | ||
| European Innovation Council | Accelerator/Incubator | Minority | ||
| Angel (individual) | Minority |
Cellevate FAQs
-
When was Cellevate founded?
Cellevate was founded in 2014.
-
Where is Cellevate headquartered?
Cellevate is headquartered in Lund, Sweden.
-
What is the size of Cellevate?
Cellevate has 23 total employees.
-
What industry is Cellevate in?
Cellevate’s primary industry is Drug Discovery.
-
Is Cellevate a private or public company?
Cellevate is a Private company.
-
What is Cellevate’s current revenue?
The current revenue for Cellevate is .
-
How much funding has Cellevate raised over time?
Cellevate has raised $10.5M.
-
Who are Cellevate’s investors?
Almi Invest, Industrifonden, Onsight Ventures, European Innovation Council, and are 5 of 7 investors who have invested in Cellevate.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process